Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Renishaw invests in D3 Technologies to exploit SERS technology

Renishaw : 10 July, 2007  (New Product)
Renishaw has acquired a 75 percent interest in D3 Technologies, a company set up in collaboration with the University of Strathclyde and others to exploit certain patents related to Surface Enhanced Raman Spectroscopy (SERS) and to develop SERS for molecular diagnostics and trace detection.
Renishaw’s investment in D3 will comprise cash of 1.85 million and instrumentation, with a combined value of approximately 5m over the next five years.

Part of the investment has been used by D3 to purchase for 850,000 the business and assets of the analytical business unit operated by Mesophotonics, a spin-out company from the University of Southampton. The analytical business unit develops and manufactures substrates used in SERS applications.

Combining the SERS technology and biochemistry expertise of the University of Strathclyde with the Klarite substrate technology of Mesophotonics analytical business unit offers a broad range of product opportunities to exploit in the growing healthcare diagnostics and forensic markets.

As a leading supplier of Raman instrumentation Renishaw has a vested interest in the development of Raman spectroscopy and its applications into new and developing markets.

Renishaw’s principal business is the design, manufacture and sale of advanced precision metrology and inspection equipment and analytical systems. Over 90 percent of its sales are exported internationally through its world-wide network of subsidiaries and distributors.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo